Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Crescent Biopharma, Inc. - Common Stock
(NQ:
CBIO
)
13.00
+0.09 (+0.70%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Crescent Biopharma, Inc. - Common Stock
< Previous
1
2
Next >
Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
November 12, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
November 03, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma to Present at November Investor Conferences
November 02, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC
October 15, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
October 06, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
October 05, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
September 25, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
September 09, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma to Present at September Investor Conferences
September 03, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
August 03, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
July 30, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
July 23, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 16, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
July 14, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
July 14, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
June 26, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
June 11, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma to Present at June Investor Conferences
June 02, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
May 29, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
May 21, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
May 12, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma to Present at May Investor Conferences
May 06, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
April 29, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
April 24, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
March 27, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
March 06, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 26, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma to Present at March Investor Conferences
February 23, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
February 19, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
February 18, 2026
From
Crescent Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1